Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 7
Submit an article Journal homepage
3,843
Views
62
CrossRef citations to date
0
Altmetric
Brief Report

K27M-mutant histone-3 as a novel target for glioma immunotherapy

Katharina OchsDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany;National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Martina OttDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany;National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Theresa BunseDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany;National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of Neurology, University Hospital Mannheim, Mannheim, Germany
,
Felix SahmDepartment of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Lukas BunseDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany;National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Katrin DeumelandtDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany;National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Jana K. SonnerDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany;National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, GermanyORCID Iconhttp://orcid.org/0000-0002-4700-272X
ORCID Icon,
Melanie KeilDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany;National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany;Immune Monitoring Unit, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
,
Andreas von DeimlingDepartment of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Wolfgang WickDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany;National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
&
Michael PlattenDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany;National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany;DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of Neurology, University Hospital Mannheim, Mannheim, Germany;Immune Monitoring Unit, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, GermanyCorrespondence[email protected]
 show all
Article: e1328340 | Received 10 Apr 2017, Accepted 05 May 2017, Published online: 05 Jul 2017

References

  • NCT Clinical Trial Registration Number NCT02017717 (ClinicalTrials.gov); A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143).
  • Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512:324-7; PMID:25043048; https://doi.org/10.1038/nature13387
  • NCT Clinical Trial Registration Number NCT02193347; IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST).
  • NCT Clinical Trial Registration Number NCT02454634; Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16).
  • Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482:226-31; PMID:22286061; https://doi.org/10.1038/nature10833
  • Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, Zapatka M, Northcott PA, Sturm D, Wang W et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 2013; 24:660-72; PMID:24183680; https://doi.org/10.1016/j.ccr.2013.10.006
  • Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013; 340:857-61; PMID:23539183; https://doi.org/10.1126/science.1232245
  • Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012; 44:251-3; PMID:22286216; https://doi.org/10.1038/ng.1102
  • Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DTW, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22:425-37; PMID:23079654; https://doi.org/10.1016/j.ccr.2012.08.024
  • Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; https://doi.org/10.1038/nature10755
  • Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19:747-52; PMID:23644516; https://doi.org/10.1038/nm.3161
  • Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 2008; 24:1397-8; PMID:18413329; https://doi.org/10.1093/bioinformatics/btn128
  • Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520:692-6; PMID:25901682; https://doi.org/10.1038/nature14426
  • Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D et al. Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest 2015; 125:593-606; PMID:25555220; https://doi.org/10.1172/JCI77780
  • Pajot A, Michel ML, Fazilleau N, Pancre V, Auriault C, Ojcius DM, Lemonnier FA, Lone YC. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 2004; 34:3060-9; PMID:15468058; https://doi.org/10.1002/eji.200425463
  • Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, Hochstrasser DF. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 1999; 112:531-52; PMID:10027275
  • Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad SciUSA 2014; 111:409-14; PMID:24367102; https://doi.org/10.1073/pnas.1314469111

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.